PDCD1 and non-small cell lung carcinoma: Additionally, anti-CTLA-4 therapy combined with an anti-PD-1 antibody has a positive effect on PD-L1 negative NSCLC [5], while anti-PD-1 monotherapy has demonstrated lower efficacy [26, 27].